Identification of Biomarkers for PKD1 Using Urinary Exosomes
Marie C. Hogan(Mayo Clinic), Christopher J. Ward(University of Kansas Medical Center), Jamie L. Sundsbak(Mayo Clinic), Jason L. Bakeberg(Mayo Clinic), John C. Lieske(Mayo Clinic), Amber J. Harmon(Hypertension Institute), Kenneth L. Johnson(Langley Research Center), Benjamin J. Madden(Mayo Clinic), Vladimir G. Gainullin(Exact Sciences (United States)), Roman M. Zenka(Mayo Clinic in Florida), Vicente E. Torres(Mayo Clinic in Arizona), María V. Irazabal, Daniel McCormick(Mayo Clinic), Peter C. Harris(Mayo Clinic), Christina M. Heyer(Mayo Clinic), M. Cristine Charlesworth(Mayo Clinic)
Cited by 133
Related Papers
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
|Kidney International|2015|602
Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease
|New England Journal of Medicine|2014|524
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|509
Mutations in GANAB , Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease
|The American Journal of Human Genetics|2016|463
Polycystin-2, the protein mutated in autosomal dominant polycystic kidney disease (ADPKD), is a Ca <sup>2+</sup> -permeable nonselective cation channel
|Proceedings of the National Academy of Sciences|2000|447